PDPN and cancer: For example, designing CARs to target cancer-specific post-translational modifications such as Tn-glycosylated podoplanin (Tn-PDPN) (128) would be expected to result in fewer off-cancer effects as the 237Ab-derived 237 CAR T cells target Tn-PDPN, which is not present on normal tissue.